Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Trinity Biotech ( (TRIB) ) has shared an update.
On May 1, 2026, Trinity Biotech appointed industry veteran Jerry Lydon as Head of North America Commercial Operations, a move aimed at strengthening sales execution, channel management, and profitability as the company shifts from restructuring to growth. The appointment is closely tied to the upgraded Premier HbA1c 9210 platform, which secured the International Federation of Clinical Chemistry’s 2026 Gold classification, and to commercial planning for pipeline products within its New York reference lab, signaling a push to translate recent operational investments into higher-quality revenue.
The company reported that outsourced manufacturing for its TrinScreen HIV test has scaled to target levels by early Q2 2026 and that Uni-Gold HIV production under the new model began in Q2 2026, both expected to support revenue and margins from Q2 onward. For Q4 2025, Trinity posted revenue of $11.1 million, down from $15.9 million a year earlier due to global HIV testing market disruption and manufacturing transition effects, but improved gross margin to 35.2% and sharply reduced adjusted EBITDA losses, despite a $17.5 million net loss inflated by a one-off $10 million financing-related charge.
For the full year 2025, revenue fell to $43.8 million from $61.6 million in 2024, driven mainly by lower point-of-care HIV and hemoglobin sales amid funding shifts and planned production changes, yet gross margin rose to 38.6% and adjusted EBITDA losses narrowed to $5.9 million, even as net loss widened to $37.4 million due to the same non-recurring financing charge. Taken together, the leadership change, operational milestones in outsourced HIV manufacturing, and improving profitability metrics suggest Trinity is positioning its streamlined cost base and enhanced product portfolio for a return to growth, though near-term results remain pressured by market headwinds and legacy financing costs.
Spark’s Take on TRIB Stock
According to Spark, TipRanks’ AI Analyst, TRIB is a Neutral.
Overall score is held down primarily by weak financial performance (sharp TTM revenue decline, deep losses, negative equity, and negative free cash flow). Technicals are only mildly supportive with mixed trend signals, and valuation provides limited support due to a negative P/E and no dividend yield data.
To see Spark’s full report on TRIB stock, click here.
More about Trinity Biotech
Trinity Biotech plc is a commercial-stage diagnostics and health technology company based in Ireland, focused on core laboratory and point-of-care testing solutions, including its Premier HbA1c 9210 platform for blood glucose monitoring and HIV rapid tests such as TrinScreen and Uni-Gold. The company also operates a New York State-approved reference laboratory and is developing proprietary assays including EpiCapture for prostate cancer monitoring and PrePsia for early-pregnancy preeclampsia risk assessment, targeting both global health and specialized clinical markets.
Over the past two years, Trinity has pursued a Comprehensive Transformation Plan to simplify its operating footprint, consolidate manufacturing, and improve margins, moving from implementation toward extracting operating leverage across geographies, particularly in North America.
Average Trading Volume: 178,166
Technical Sentiment Signal: Strong Sell
Current Market Cap: $11.97M
See more insights into TRIB stock on TipRanks’ Stock Analysis page.